ArticleJournal of virology2026
ANXA2 suppresses antiviral immunity by impeding STING Golgi translocation and disrupting the TBK1/IKKε-IRF3 axis.
Article in Journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Upon viral infection, the cGAS-STING axis is pivotal for initiating type I interferon (IFN) production against DNA viruses. In this study, we identified Annexin A2 (ANXA2) as a novel and potent negative regulator of this antiviral pathway. Overexpression of ANXA2 inhibits herpes simplex virus-1 (HSV-1)-induced IFN-β production, thereby promoting viral replication, whereas ANXA2 deficiency enhances IFN responses and restricts HSV-1 replication. Mechanistically, ANXA2 operates through a dual mechanism. First, it interacts with the transmembrane domain of STING and inhibits its agonist-triggered translocation from the endoplasmic reticulum to the Golgi apparatus, a step essential for STING activation. Second, ANXA2 binds to the nuclear export signal of IRF3, competing with the kinases TBK1 and IKKε for IRF3 interaction. This disrupts the formation of the TBK1-IKKε-IRF3 complex, thereby suppressing IRF3 phosphorylation and nuclear translocation. This function is independent of its canonical binding partner S100A10 but requires ANXA2's calcium-binding capacity. Crucially, IMPORTANCE: The cGAS-STING axis is essential for host resistance to DNA virus infections by regulating type I interferon (IFN) production. This study is significant because it identifies Annexin A2 (ANXA2) as a previously unrecognized and potent negative regulator of the host antiviral response against DNA viruses like herpes simplex virus-1. The findings demonstrate that ANXA2 suppresses type I interferon production through a dual mechanism: by inhibiting the critical transport of STING to the Golgi apparatus and by disrupting the kinase activity of TBK1/IKKε required for IRF3 activation. This role is independent of its known partner S100A10, revealing a novel function for ANXA2. The validation in knockout mice, which showed enhanced IFN production and restricted viral replication, confirms its physiological importance
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.